Tumour but not stromal expression ofβ3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour but not stromal expression ofβ3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 235, Issue 5, Pages 760-772
Publisher
Wiley
Online
2014-11-29
DOI
10.1002/path.4490
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells
- (2014) Delphine Denoyer et al. GROWTH FACTORS
- Vascular Endothelial Growth Factor-d Modulates Caliber and Function of Initial Lymphatics in the Dermis
- (2013) Sophie Paquet-Fifield et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
- (2012) Christian Manegold et al. INVESTIGATIONAL NEW DRUGS
- A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
- (2012) Kevin B. Kim et al. MELANOMA RESEARCH
- Integrin Targeted Therapeutics
- (2012) Melissa Millard et al. Theranostics
- Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis
- (2011) Nicole Kusuma et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
- (2011) Steven J. O’Day et al. INVESTIGATIONAL NEW DRUGS
- Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach
- (2011) Masami Kadowaki et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
- (2011) Kenjiro Sawada et al. Journal of Oncology
- Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions
- (2010) Jochen G. Schneider et al. BONE
- A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma
- (2010) Peter Hersey et al. CANCER
- Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
- (2010) Ajjai Alva et al. INVESTIGATIONAL NEW DRUGS
- Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration
- (2010) D. Denoyer et al. JOURNAL OF NUCLEAR MEDICINE
- The platelet contribution to cancer progression
- (2010) N. M. BAMBACE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- β 3 -Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer
- (2009) Swayamjot Kaur et al. AMERICAN JOURNAL OF PATHOLOGY
- Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions
- (2009) Jane Wenzel et al. CLINICAL & EXPERIMENTAL METASTASIS
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
- (2008) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started